Humanised anti-mag antibody or functional fragment thereof
AssigneeGlaxo Group Limited
InventorsJonathan Henry Ellis, Volker Germaschewski
Life of this patent
Estimating the term…
Abstract
The present invention relates to altered antibodies to myelin associated glycoprotein (MAG), pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders.
Claims15
A humanised anti-MAG antibody which binds to and neutralizes MAG comprising, a heavy chain variable domain selected from the group consisting of:
- SEQ ID No. 13, SEQ ID No. 14, and SEQ ID No. 15, and a light chain variable domain selected from the group consisting of:
- SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 18, and SEQ ID No. 19.
A humanised anti-MAG antibody which binds to and neutralizes MAG comprising:
- a heavy chain variable region of SEQ ID No. 13 and
- a light chain variable region of SEQ ID No. 16.
A humanised anti-MAG antibody which binds to and neutralizes MAG comprising:
- a heavy chain variable region of SEQ ID No. 13 and
- a light chain variable region of SEQ ID No. 17.
A humanised anti-MAG antibody which binds to and neutralizes MAG comprising:
- a heavy chain variable region of SEQ ID No. 13 and
- a light chain variable region of SEQ ID No. 18.
A humanised anti-MAG antibody which binds to and neutralizes MAG comprising:
- a heavy chain variable region of SEQ ID No. 13 and
- a light chain variable region of SEQ ID No. 19.
A humanised anti-MAG antibody which binds to and neutralizes MAG comprising:
- a heavy chain variable region of SEQ ID No. 14 and
- a light chain variable region of SEQ ID No. 16.
A humanised anti-MAG antibody which binds to and neutralizes MAG comprising:
- a heavy chain variable region of SEQ ID No. 14 and
- a light chain variable region of SEQ ID No. 17.
A humanised anti-MAG antibody which binds to and neutralizes MAG comprising:
- a heavy chain variable region of SEQ ID No. 14 and
- a light chain variable region of SEQ ID No. 18.
A humanised anti-MAG antibody which binds to and neutralizes MAG comprising:
- a heavy chain variable region of SEQ ID No. 14 and
- light chain variable region of SEQ ID No. 19.
A humanised anti-MAG antibody which binds to and neutralizes MAG comprising:
- a heavy chain variable region of SEQ ID No. 15 and
- a light chain variable region of SEQ ID No. 16.
A humanised anti-MAG antibody which binds to and neutralizes MAG comprising:
- a heavy chain variable region of SEQ ID No. 15 and
- a light chain variable region of SEQ ID No. 17.
A humanised anti-MAG antibody which binds to and neutralizes MAG comprising:
- a heavy chain variable region of SEQ ID No. 15 and
- a light chain variable region of SEQ ID No. 18.
A humanised anti-MAG antibody which binds to and neutralizes MAG comprising:
- a heavy chain variable region of SEQ ID No. 15 and
- a light chain variable region of SEQ ID No. 19.
Dependencies are inferred from the claim text.